Galecto Biotech Raises $275M, Converts Preferred Shares, Boosting Capital & Confidence
Galecto Biotech’s $275 m equity raise and preferred‑to‑common conversion adds 8.7 m shares, boosting capital for fibrosis & cancer trials while diluting shares—insider buys signal confidence in future growth.
3 minutes to read